AIML Aligns Leadership for Growth and Shareholder Value Creation
AIML Aligns Leadership for Growth and Shareholder Value Creation
Paul Duffy Appointed Executive Chairman of the Board
Peter Kendall Joins Board
Seasoned Advisors Mark Orsmond and Michael Nemirow to Support AIML's Corporate Development Initiatives
保羅·達菲被任命爲董事會執行主席
彼得·肯達爾加入董事會
經驗豐富的顧問馬克·奧斯蒙德和邁克爾·尼米羅將支持AIML的企業發展計劃
VANCOUVER, BC / ACCESS Newswire / March 14, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce key updates to its Board of Directors ("Board") as the Company enters an exciting new phase of growth and commercialization.
加拿大卑詩省溫哥華 / ACCESS Newswire / 2025年3月14日 / AI/ML Innovations Inc.("AIML"或"公司")(CSE:AIML)(OTCQB:AIMLF)(FWB:42FB)欣然宣佈在公司迎來激動人心的增長與商業化新階段之際,董事會("董事會")的關鍵更新。
Paul Duffy, AIML's Chief Executive Officer, and Peter Kendall, AIML's President and Chief Commercialization Officer, have both been appointed to the Board. Mr. Duffy has also assumed the role of Executive Chairman, Simultaneously, Mark Orsmond, outgoing Executive Chair of the Board, and Michael Nemirow have stepped down from the Board and continue their involvement as strategic advisors.
AIML的首席執行官保羅·達菲和AIML的總裁兼首席商業化官彼得·肯達爾均已被任命爲董事會成員。達菲先生還同時擔任執行主席職務。同時,離任的董事會執行主席馬克·奧斯蒙德和邁克爾·尼米羅已辭去董事會職務,並繼續以戰略顧問的身份參與。
These changes reflect AIML's strategic commitment to aligning with the Company's forward-looking focus on commercial execution, market penetration, and strategic partnerships. As AIML continues to advance its innovative portfolio of AI-driven healthcare technologies, this Board realignment ensures the Company is structured to accelerate growth, provide direct industry experience, and drive shareholder value.
這些變動反映了AIML在與公司的前瞻性聚焦於商業執行、市場滲透和戰略合作伙伴關係對齊的戰略承諾。隨着AIML繼續推進其基於人工智能的醫療技術創新組合,這一董事會的重新調整確保公司結構旨在加速增長,提供直接的行業經驗,並推動股東價值。
Paul Duffy, CEO and newly appointed Chairman of the Board, commented:
"We are entering an exciting new chapter at AIML, one defined by focus, execution, and scalable impact. Strengthening our Board with more industry participants to enhance a commercialization lens is a key part of our strategic evolution, and I'm honored to now serve in a governance capacity alongside Peter Kendall. I would like to express my deep gratitude to both Mark and Michael for their dedication, insights, and leadership during a foundational period for the Company. In particular, we are very grateful to Mark for the top-tier medical and professional team that is now part of our Company, and I look forward to continuing to work closely with him in his new advisory role."
保羅·達菲,首席執行官及新任董事會主席,評論道:
「我們正在進入AIML激動人心的新篇章,這一篇章以專注、執行和可擴展的影響力爲特徵。通過增加更多行業參與者以增強商業化視角來加強我們的董事會是我們戰略演變的關鍵部分,我很榮幸能與彼得·肯達爾共同擔任治理職務。我想對馬克和邁克爾在公司基礎性時期的奉獻、見解和領導力表示深深的感謝。特別是,我們非常感謝馬克爲我們公司現在擁有的頂級醫療和專業團隊所做出的貢獻,我期待在他的新顧問角色中繼續與他密切合作。」
As part of this transition, Mark Orsmond and Michael Nemirow will continue to play a pivotal role in the Company's growth trajectory, supporting corporate development initiatives, strategic partnerships, and commercialization strategies.
作爲此次過渡的一部分,馬克·奧斯蒙德和邁克爾·內米羅將繼續在公司的成長軌跡中發揮關鍵作用,支持企業發展計劃、戰略合作伙伴關係和商業化戰略。
AIML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health. These leadership transitions mark a meaningful step forward in realizing that vision.
AIML 始終堅持其使命,在人工智能與盈健醫療的交匯處提供突破性解決方案。這些領導層的變動標誌着實現該願景的重要一步。
For more information about AIML:
有關AIML的更多信息:
For detailed information please see AIML's website or the Company's filed documents at .
有關詳細信息,請查看AIML的官方網站或公司提交的文件。 .
Contact:
Blake Fallis
(778) 405-0882
info@aiml-innovations.com
聯繫:
布萊克·法利斯
(778) 405-0882
info@aiml-innovations.com
About AI/ML Innovations Inc.
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its wholly-owned subsidiaries, Quantum Sciences Ltd. and NeuralCloud Solutions Inc, strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 11.11% currently owned by AIML), AI Rx Inc. (70% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
關於AI/ML創新公司。
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its wholly-owned subsidiaries, Quantum Sciences Ltd. and NeuralCloud Solutions Inc, strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 11.11% currently owned by AIML), AI Rx Inc. (70% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
On behalf of the Board of Directors:
Paul Duffy, Chairman
代表董事會:
Paul Duffy, Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
The Canadian Securities Exchange has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward- looking statements" within the meaning of the securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will be issued as a result of a pending patent application or, if issued, whether it will be issued in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time at sedarplus.ca. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third- party websites.
加拿大證券交易所並未對公司的優點作出任何評估,也未批准或否決本新聞稿的內容。加拿大證券交易所和市場監管機構(根據加拿大證券交易所政策中定義的術語)對本稿的充分性或準確性不承擔任何責任。本新聞稿包含證券法意義上的「前瞻性陳述」。諸如「預計」、「預期」、「意圖」、「計劃」、「相信」、「尋求」、「估計」等詞及此類詞的變體旨在識別前瞻性陳述。前瞻性陳述不是歷史事實,而是基於管理層當前的期望、信念和預測,其中許多本質上是不確定的。這些期望、信念和預測是善意表達的。然而,無法保證管理層的期望、信念和預測會實現,實際結果可能與前瞻性陳述中所表達或指示的內容存在重大差異。此外,我們無法保證任何專利會因待決的專利申請而被授予,或者如果被授予,是否會以對我們有利的形式發放。前瞻性陳述受到風險和不確定性的影響,這可能導致實際表現或結果與前瞻性陳述中表達的內容存在重大差異。有關影響公司的風險和不確定性的更詳細描述,請參閱公司不時在sedarplus.ca上提交的報告。前瞻性陳述僅在陳述日期有效。公司不承擔任何更新前瞻性陳述以反映實際結果、後續事件或情況、假設變化或影響前瞻性信息的其他因素變化的義務,除非適用的證券法要求。如果公司更新一項或多項前瞻性陳述,不應推斷公司將在其後或其他前瞻性陳述中做出額外更新。爲方便起見,已提供對網站的引用和鏈接,所包含的信息並未通過引用納入本新聞稿。公司對第三方網站的內容不承擔任何責任。
SOURCE: AI/ML Innovations, Inc.
來源:AI/ML創新公司,Inc.
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因